ASH 2024 | Characteristics and outcomes of patients with AML and FLT3-TKD mutations
Sankalp Arora
• 7 Dec 2024
Sankalp Arora, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the characteristics and outcomes of patients with acute myeloid leukemia (AML) and FLT3-TKD mutations. Dr Arora notes that NPM1 mutations often co-occur with FLT3-TKD, which affects patient responses to various therapies. He then discusses the impact of venetoclax and FLT3 inhibitors on patient survival and emphasizes the importance of considering both mutations when assessing prognosis. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
